- Home
- NPWR vs GALT Comparison
NPWR vs GALT Comparison
Compare NPWR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPWR | GALT |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.9M | 199.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | NPWR | GALT |
|---|---|---|
| Price | $1.54 | $2.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 711.2K | 340.3K |
| Earning Date | 03-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.48 | $1.15 |
| 52 Week High | $5.20 | $7.13 |
Technical Indicators
Market Signals| Indicator | NPWR | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 39.67 |
| Support Level | N/A | $2.59 |
| Resistance Level | $2.17 | $3.32 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 2.08 | 5.56 |
Price Performance
Historical ComparisonAbout NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.